Impact of central antagonist of cholecystokinin-1 receptors GB-115 on cognitive functions in patients with Generalized Anxiety Disorder

Dorofeeva O, Metlina M, Chepeliuk A, Vinogradova M

European psychiatry : the journal of the Association of European Psychiatrists1 Sept 2022

PMCIDPMC9563656PepBankPUB-92543121

Download PDF Source pageAsk about this study

Summary

Introduction Generalized anxiety disorder (GAD) is associated with reduced attention, inhibition, decrease of processing speed. The impact of a new peptide antagonist of central cholecystokinin-1 receptors (GB-115) on cognitive processes in patients with GAD is reported. Objectives To research the cognitive effects of GB-115 in patients with GAD. Methods 25 patients with GAD in ICD-10 (mean age 35,76±8,55 years) treated with GB-115 in clinically relevant dose (6 mg/d) were enrolled to the study. The evaluation of cognitive functions was conducted at background, Day 3, Day 7, Day 14 and Day 21. The laboratory test toolkit included reaction time test, Shulte-Platonov tables, attention tests (using hardware and software complex “NeuroSoft-PsychoTest”). Statistical significance was ascertained by Wilcoxon signed-rank test. Results Speed of reaction time increased on the Day 7 (418,17±61,49 msec, p≤0,01), the Day 14 (422,25±70,69 msec, p≤0,01) and the Day 21 of treatment (406,5±52,79 msec, p≤0,01) in comparison with background (449,19±64,91). Attention parameters improved on the Day 3 (305,95±45,31 msec, p≤0,05) and the Day 21 of treatment (300,14±47,74 msec, p≤0,05) in comparison with the background (316,41±42,35 msec). Decrease of time in performance of tables of Shulte-Platonov was also observed on the Day 7 (59,40±13,71 sec, p≤0,01), the Day 14 (57,88±12,82 sec, p≤0,01) and the Day 21 (53,40±13,19 sec, p≤0,01) in comparison with the background (68,84±16,78 sec). Conclusions GB-115 revealed cognitive effects such as an increase of processing speed and improvement of different aspects of attention (attentional resource allocation, attention span and switching) after the Day 7 of treatment. Disclosure No significant relationships.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, reaction time decreased versus background during GB‑115 treatment.
In plain wordsIn patients with generalized anxiety disorder, reaction time decreased versus background during GB‑115 treatment.
Peptide
GB-115
Outcome
DecreaseReaction time
Study
n = 25
Comparator
Background
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
6 mg/dAs given in this study (human).
Measurements
Reaction time
418.17 msec
Day 7
Reaction time
422.25 msec
Day 14
Reaction time
406.5 msec
Day 21
Reaction time
449.19 msec
background
Source sentences
Summary
Speed of reaction time increased on the Day 7 (418,17±61,49 msec, p≤0,01), the Day 14 (422,25±70,69 msec, p≤0,01) and the Day 21 of treatment (406,5±52,79 msec, p≤0,01) in comparison with background (449,19±64,91).
2 context sentences(design, population, supporting numbers)
Summary · context
25 patients with GAD in ICD-10 (mean age 35,76±8,55 years) treated with GB-115 in clinically relevant dose (6 mg/d) were enrolled to the study.
Summary · context
The evaluation of cognitive functions was conducted at background, Day 3, Day 7, Day 14 and Day 21.
Show in the study text Report a problemFND-9254312101
02HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, attention task times improved versus background during GB‑115 treatment.
In plain wordsIn patients with generalized anxiety disorder, attention task times improved versus background during GB‑115 treatment.
Peptide
GB-115
Outcome
DecreaseAttention parameters
Study
n = 25
Comparator
Background
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
6 mg/dAs given in this study (human).
Measurements
Attention parameter
305.95 msec
Day 3
Attention parameter
300.14 msec
Day 21
Attention parameter
316.41 msec
background
Source sentences
Summary
Attention parameters improved on the Day 3 (305,95±45,31 msec, p≤0,05) and the Day 21 of treatment (300,14±47,74 msec, p≤0,05) in comparison with the background (316,41±42,35 msec).
2 context sentences(design, population, supporting numbers)
Summary · context
25 patients with GAD in ICD-10 (mean age 35,76±8,55 years) treated with GB-115 in clinically relevant dose (6 mg/d) were enrolled to the study.
Summary · context
The evaluation of cognitive functions was conducted at background, Day 3, Day 7, Day 14 and Day 21.
Show in the study text Report a problemFND-9254312102
03HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, Shulte-Platonov table performance time decreased versus background during GB‑115 treatment.
In plain wordsIn patients with generalized anxiety disorder, table task time decreased versus background during GB‑115 treatment.
Peptide
GB-115
Outcome
DecreaseShulte-Platonov table performance time
Study
n = 25
Comparator
Background
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
6 mg/dAs given in this study (human).
Measurements
Table performance time
59.4 sec
Day 7
Table performance time
57.88 sec
Day 14
Table performance time
53.4 sec
Day 21
Table performance time
68.84 sec
background
Source sentences
Summary
Decrease of time in performance of tables of Shulte-Platonov was also observed on the Day 7 (59,40±13,71 sec, p≤0,01), the Day 14 (57,88±12,82 sec, p≤0,01) and the Day 21 (53,40±13,19 sec, p≤0,01) in comparison with the background (68,84±16,78 sec).
2 context sentences(design, population, supporting numbers)
Summary · context
25 patients with GAD in ICD-10 (mean age 35,76±8,55 years) treated with GB-115 in clinically relevant dose (6 mg/d) were enrolled to the study.
Summary · context
The evaluation of cognitive functions was conducted at background, Day 3, Day 7, Day 14 and Day 21.
Show in the study text Report a problemFND-9254312103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.